Fluoxetine hydrochloride CAS No: 56296-78-7 is the world's first antidepressant drug with selective serotonin reuptake inhibitors (SSRIs) on the market. The company was the first to successfully develop it. 14 years after the discovery of fluoxetine, in 1986, Belgium first approved its listing Chemicalbook for the treatment of depression. At the end of 1987, it was approved by the FDA to enter the U.S. market under the trade name Prozac. It became the best-selling antidepressant in the U.S. and pioneered A new era of effective treatment of depression and good safety. It was subsequently listed in many Western countries such as the United Kingdom and France, and is now sold globally.
Because fluoxetine is the first 5-HT reuptake inhibitor antidepressant to be marketed, it has a different structure and pharmacological mechanism from the previous TCA antidepressants. It has definite curative effect and mild side effects. It has been favored after it goes on the market, and its sales have increased significantly year by year. Since the research and development of fluoxetine by Eli Lilly in the 1970s, Chemicalbook has created many brilliances, which can be called a generation of legends and opened a new chapter in the treatment of depression. Although the market has declined after 2001, it is still one of the commonly used drugs for antidepressant treatment.
Fluoxetine can block 5-HT2A receptors and restore DA and NE levels by inhibiting 5-HT2A receptors. At the same time, fluoxetine can also release the inhibition of the release of NE and DA from γ-aminobutyric acid (GABA) neurons through the 5-HT2C receptor. In addition to increasing the 5-HT concentration in the synaptic cleft, it is precisely based on the effect of fluoxetine on 5-HT2A and 5-HT2C that it directly and indirectly restores the levels of DA and NE, and has the characteristics of NE and DA de-inhibition ( NDDI).
Fluoxetine hydrochloride is not only used for various types of depression, it is especially suitable for depressive symptoms associated with organic diseases and senile depression. It is also used to treat depression after schizophrenia. It is also used for obsessive-compulsive disorder, phobia, anxiety symptoms of depression, bulimia nervosa, weight loss and as an auxiliary treatment for smoking cessation.
